NSAID labeling cost projection grows
This article was originally published in The Tan Sheet
Executive Summary
FDA raises its estimate of industry costs in a final rule requiring organ-specific label warnings for OTC products containing acetaminophen or nonsteroidal anti-inflammatory drugs by April 29, 2010. The revised rulemaking bumps up first-year, one-time, industry-wide re-labeling costs to $62.7 million from $32.6 million, according to a June 30 Federal Register notice. FDA says its April 29 estimate of the products affected by the final rule underestimated the proportion of affected NSAID products, which will need expanded inner blister pack containers and outer cartons to accommodate the additional warnings. Packaging for OTC acetaminophen will not need to be made larger, FDA says. FDA still projects the total number of SKUs affected at 18,000, while industry consultant Eastern Research Group says it could be as high as 25,000 (1"The Tan Sheet" May 4, 2009)
You may also be interested in...
FDA Expands Acetaminophen, NSAID Labeling Beyond Tentative Final Rule
FDA's final rule for OTC products containing acetaminophen or nonsteroidal anti-inflammatory drugs requires warnings and revisions that go beyond changes the agency proposed in a 2006 tentative final rule
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.